Blue Jet Healthcare's record carries a clean audit opinion for FY2025-26, but that clean opinion sits alongside a cluster of unresolved regulatory and governance issues. The most material are a ₹193.39 crore income-tax demand under appeal before higher authorities, a recurring pattern of audit-trail and internal-control gaps, and a sharp fall in operating cash flow just as a ₹1,000-crore capex programme accelerates.
Key findings
- Clean audit opinions, but the same audit-trail and control gaps flagged for three years
Major- KKC & Associates LLP issued an unqualified opinion on the FY2025-26 standalone financial statements, dated 25 May 2026, with no Emphasis of Matter or material-uncertainty paragraph, but the report did list "Appropriateness of Revenue Recognition" as a Key Audit Matter. The auditor noted it could not confirm whether the audit-trail feature operated throughout the year in the payroll software, and that inventory records were kept in spreadsheets without an edit log until 7 December 2025. The internal financial controls opinion has repeated the same documentation weakness for three consecutive years, and revenue recognition was flagged as a Key Audit Matter in each of FY2024, FY2025 and FY2026. - Three properties with gross carrying value of ₹605.82 million remain titled in a merged entity's name
Major- Blue Jet reports no subsidiaries, associates or joint ventures, yet three immovable properties - leasehold land of ₹14.75 million held since 2004, leasehold land of ₹18.24 million held since 2016, and a building of ₹572.83 million held since 2005 - are still titled in the name of Blue Circle Organics Private Limited. The NCLT approved the merger on 19 November 2020, effective 1 April 2019, but the title transfer is described as "in process". - Operating cash flow fell sharply while a ₹1,000-crore capex programme accelerates
Major- Net cash from operations dropped to ₹45.76 crore in FY2025 from ₹241.25 crore in FY2024, while capital expenditure rose to 79.88 crore from ₹172.86 crore. The Mahad backward-integration project's capital work-in-progress reached 179.56 crore as at 31 March 2026, up from 72.46 crore a year earlier, with the overrun attributed to design changes, delayed equipment and pending clearances. Management's capex guidance for FY27 was given as both ₹250 crore and ₹400 crore without reconciliation. - Revenue and receivables are concentrated in two customers, with a sharp receivables swing
Major- Two customers accounted for 40.64% and 30.45% of product revenue in FY2026, and 84% of total trade receivables as at 31 March 2026. Total trade receivables fell 60% to ₹139.05 crore from ₹349.53 crore a year earlier. The working capital cycle stretched to 157 days in FY2025 from 92 days in FY2024. - Two regulator actions since 2023, despite filings stating no penalties imposed
Major- The Income Tax Department searched Blue Jet's premises on 5 June 2023, and the company received reassessment notices on 19 January 2024. A GST inspection under Section 67 of the MGST Act ran from 21 to 28 May 2025, citing mismatches between GSTR-3B and GSTR-2A, and the company paid around ₹5.08 crore including interest. The FY2025-26 Annual Report nonetheless states no penalty or stricture was imposed by exchanges, SEBI or statutory authorities since listing on 1 November 2023. - Depreciation-method change lifted profit by ₹14.44 crore while fire losses remain unrecovered
Major- Blue Jet switched from Written Down Value to Straight-Line Method during FY2024-25, lowering depreciation and raising pre-tax profit by ₹14.44 crore. A fire at Mahad on 3 November 2023 caused an exceptional loss of ₹9.74 crore, and a fire at Ambernath on 10 June 2023 caused a ₹1.39 crore loss, both pending insurer approval. The CFO acknowledged in Q1 FY27 that asset turns are inflated by the depreciated asset block rather than operational efficiency. - "Nil net debt" claim sits alongside rising bank-lodged balances and unfiled working-capital returns
Major- The company states net debt was nil as at 31 March 2026 and 31 March 2025, and that no borrowings were outstanding. Yet balances with banks in deposit accounts lodged in favour of various banks rose to ₹52.15 crore as at 31 March 2026 from ₹21.67 crore a year earlier. The auditor's CARO report for FY2024-25 notes working capital limits in excess of ₹5 crore secured on current assets, with quarterly returns not filed as the sanction letters do not require them.
What to watch
- Property title transfer. Completion of transfer for the three properties held in Blue Circle Organics' name, flagged in the FY2025-26 Annual Report.
- Mahad commissioning. The COO said the project was "slightly ahead of schedule" as of Q1 FY27 (June 2026), but no completion date has been given.
- FY27 capex actuals. The ₹250 crore versus ₹400 crore guidance discrepancy from Q1 FY27 remains unreconciled.
- Q2 FY27 revenue recognition. Results will confirm whether the ₹30-odd crore goods-in-transit deferred from Q1 FY27 is recognised, as management noted the September-quarter closing goods-in-transit cannot be predicted.
Bottom line: This is a disclosed and audited record with a clean statutory opinion, but the clean opinion masks a recurring set of control weaknesses and unresolved exposures. The character of the risk is cumulative: an income-tax demand from reassessment notices, properties not in the company's name two decades after acquisition, and cash flow weakening just as a large capex programme accelerates. Watch the appeal outcome, the title transfers, and whether FY27 capex and revenue recognition match the guidance given.